The role of TP53 in acute myeloid leukemia: Challenges and opportunities

p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells

(2019) Luciana P. Rangel et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

BCL2/MDM2 Inhibitor Combo Effective in AML

(2019)   Cancer Discovery

A window of opportunity trial of atorvastatin in p53-mutant and p53 wild type malignancies.

(2019) Mohammad Telfah et al.   JOURNAL OF CLINICAL ONCOLOGY

MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)

(2019) Arushi Khurana et al.   OncoTargets and Therapy

A gain-of-function p53 mutant oncogene promotes cell fate plasticity and myeloid leukemia through the pluripotency factor Foxh1

(2019) Evangelia Loizou et al.   Cancer Discovery

A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies

(2019) Steffen Boettcher et al.   SCIENCE

Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies

(2018) Robert L. Bowman et al.   Cell Stem Cell

New Insights from Studies of Clonal Hematopoiesis

(2018) Christopher J. Gibson et al.   CLINICAL CANCER RESEARCH

An Update on MDMX and Dual MDM2/X Inhibitors

(2018) Margarida Espadinha et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Somatic mutations precede acute myeloid leukemia years before diagnosis

(2018) Pinkal Desai et al.   NATURE MEDICINE

Mutant and wild-type p53 form complexes with p73 upon phosphorylation by the kinase JNK

(2018) Eric R. Wolf et al.   Science Signaling

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia

(2018) Luis A. Carvajal et al.   Science Translational Medicine

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277

(2018) Qiang Zhang et al.   Cell Death & Disease

Mutant and wild-type p53 form complexes with p73 upon phosphorylation by the kinase JNK

(2018) Eric R. Wolf et al.   Science Signaling

Dose and schedule determine distinct molecular mechanisms underlying the efficacy of the p53-MDM2 inhibitor HDM201

(2018) Sébastien Jeay et al.   CANCER RESEARCH

A Novel MCL-1 Inhibitor Combined with Venetoclax Rescues Venetoclax Resistant Acute Myelogenous Leukemia

(2018) Haley E. Ramsey et al.   Cancer Discovery

Senescence-associated reprogramming promotes cancer stemness

(2017) Maja Milanovic et al.   NATURE

The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions

(2017) Hamid Bolouri et al.   NATURE MEDICINE

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease

(2017) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro

(2017) Nélida I. Noguera et al.   Oncotarget

The Roles of MDM2 and MDMX in Cancer

(2016) Orit Karni-Schmidt et al.   Annual Review of Pathology-Mechanisms of Disease

Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument

(2016) Pascal Furet et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

p53−/−synergizes with enhancedNrasG12Dsignaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia

(2016) Jingfang Zhang et al.   BLOOD

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

(2016) K. H. Metzeler et al.   BLOOD

TP53mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes

(2016) Chun-Kang Chang et al.   BRITISH JOURNAL OF HAEMATOLOGY

TP53mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

(2016) Tapan M. Kadia et al.   CANCER

A BH3 Mimetic for Killing Cancer Cells

(2016) Douglas R. Green   CELL

Pharmacological activation of wild-type p53 in the therapy of leukemia

(2016) Kensuke Kojima et al.   EXPERIMENTAL HEMATOLOGY

Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

(2016) B. Reis et al.   HAEMATOLOGICA

TP53Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data

(2016) Liacine Bouaoun et al.   HUMAN MUTATION

p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status

(2016) A Quintás-Cardama et al.   LEUKEMIA

DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway

(2016) Alejandro Parrales et al.   NATURE CELL BIOLOGY

Introducing STRaNDs: shuttling transcriptional regulators that are non-DNA binding

(2016) Min Lu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

(2016) John S. Welch et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

(2016) M. Konopleva et al.   Cancer Discovery

Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation

(2016) Yoav Shetzer et al.   Cold Spring Harbor Perspectives in Medicine

Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End

(2016) Amanda R. Wasylishen et al.   Cold Spring Harbor Perspectives in Medicine

The Role of MDM2 Amplification and Overexpression in Tumorigenesis

(2016) Jonathan D. Oliner et al.   Cold Spring Harbor Perspectives in Medicine

Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

(2016) B. Reis et al.   HAEMATOLOGICA

P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia

(2016) Stefania Trino et al.   Frontiers in Pharmacology

Acute myeloid leukaemia

(2016) Asim Khwaja et al.   Nature Reviews Disease Primers

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

(2015) D. P. Steensma et al.   BLOOD

Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia

(2015) Christine M. Gronseth et al.   CANCER

Effective Targeting of the P53-MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia

(2015) J. Richmond et al.   CLINICAL CANCER RESEARCH

The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents

(2015) J. Canon et al.   MOLECULAR CANCER THERAPEUTICS

Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth

(2015) Jiajun Zhu et al.   NATURE

Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice

(2014) A. Stoddart et al.   BLOOD

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

(2014) R. C. Lindsley et al.   BLOOD

MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia

(2014) Chong Chen et al.   CANCER CELL

A Code for RanGDP Binding in Ankyrin Repeats Defines a Nuclear Import Pathway

(2014) Min Lu et al.   CELL

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

(2014) Daqing Sun et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of a Small Molecule MDM2 Inhibitor (AMG 232) for Treating Cancer

(2014) Yosup Rew et al.   JOURNAL OF MEDICINAL CHEMISTRY

Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells

(2014) Johanna Flach et al.   NATURE

Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia

(2014) Liran I. Shlush et al.   NATURE

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

(2014) Terrence N. Wong et al.   NATURE

Age-related mutations associated with clonal hematopoietic expansion and malignancies

(2014) Mingchao Xie et al.   NATURE MEDICINE

Drugging the p53 pathway: understanding the route to clinical efficacy

(2014) Kian Hoe Khoo et al.   NATURE REVIEWS DRUG DISCOVERY

Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence

(2014) Giulio Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Arsenic Trioxide Reactivates Proteasome-Dependent Degradation of Mutant p53 Protein in Cancer Cells in Part via Enhanced Expression of Pirh2 E3 Ligase

(2014) Wensheng Yan et al.   PLoS One

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

(2014) M. R. Corces-Zimmerman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms

(2014) Raajit Rampal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP

(2013) Min Lu et al.   CANCER CELL

Mechanisms that Regulate Stem Cell Aging and Life Span

(2013) Robert A.J. Signer et al.   Cell Stem Cell

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

(2013) Qingjie Ding et al.   JOURNAL OF MEDICINAL CHEMISTRY

Self-renewal as a therapeutic target in human colorectal cancer

(2013) Antonija Kreso et al.   NATURE MEDICINE

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice

(2013) P Basova et al.   ONCOGENE

Concise Review: Leukemia Stem Cells in Personalized Medicine

(2013) Monica L. Guzman et al.   STEM CELLS

Evading apoptosis in cancer

(2013) Kaleigh Fernald et al.   TRENDS IN CELL BIOLOGY

How I treat CML blast crisis

(2012) R. Hehlmann   BLOOD

The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans

(2012) V. Pant et al.   BLOOD

A novel hierarchical prognostic model of AML solely based on molecular mutations

(2012) V. Grossmann et al.   BLOOD

The Origin and Evolution of Mutations in Acute Myeloid Leukemia

(2012) John S. Welch et al.   CELL

The Future of Peptide-based Drugs

(2012) David J. Craik et al.   Chemical Biology & Drug Design

Mutant p53: one name, many proteins

(2012) W. A. Freed-Pastor et al.   GENES & DEVELOPMENT

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Clonal Architecture of Secondary Acute Myeloid Leukemia

(2012) Matthew J. Walter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells

(2011) T. Yahata et al.   BLOOD

TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome

(2011) F. G. Rucker et al.   BLOOD

Mechanism-specific signatures for small-molecule p53 activators

(2011) Ingeborg M.M. van Leeuwen et al.   CELL CYCLE

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

(2011) D Li et al.   CELL DEATH AND DIFFERENTIATION

PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53

(2011) R. Zandi et al.   CLINICAL CANCER RESEARCH

Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity

(2011) Y. V. Wang et al.   GENES & DEVELOPMENT

Mutant p53 Protein Is Targeted by Arsenic for Degradation and Plays a Role in Arsenic-mediated Growth Suppression

(2011) Wensheng Yan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Links between mutant p53 and genomic instability

(2011) Walter Hanel et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells

(2011) D. Li et al.   MOLECULAR CANCER RESEARCH

ChIP-on-Chip Analysis of In Vivo Mutant p53 Binding To Selected Gene Promoters

(2011) Stefania Dell'Orso et al.   OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY

A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53

(2010) Federico Bernal et al.   CANCER CELL

Reactivating the ARF-p53 axis in AML cells by targeting ULF

(2010) Delin Chen et al.   CELL CYCLE

A small molecule inhibitor of p53 stimulates amplification of hematopoietic stem cells but does not promote tumor development in mice

(2010) Katerina I. Leonova et al.   CELL CYCLE

p53-Mediated Hematopoietic Stem and Progenitor Cell Competition

(2010) Tanya Bondar et al.   Cell Stem Cell

Genomic analysis of acute myeloid leukemia: potential for new prognostic indicators

(2010) Elizabeth A Eklund   CURRENT OPINION IN HEMATOLOGY

p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal

(2010) Z. Zhao et al.   GENES & DEVELOPMENT

Puma is required for p53-induced depletion of adult stem cells

(2010) Dongping Liu et al.   NATURE CELL BIOLOGY

Irradiation Selects for p53-Deficient Hematopoietic Progenitors

(2010) Andriy Marusyk et al.   PLOS BIOLOGY

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

(2009) Jeremy M.R. Lambert et al.   CANCER CELL

The Tumor Suppressor p53 Regulates Polarity of Self-Renewing Divisions in Mammary Stem Cells

(2009) Angelo Cicalese et al.   CELL

p53 Regulates Hematopoietic Stem Cell Quiescence

(2009) Yan Liu et al.   Cell Stem Cell

Mouse models of human AML accurately predict chemotherapy response

(2009) J. Zuber et al.   GENES & DEVELOPMENT

The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia

(2009) H Seifert et al.   LEUKEMIA

Suppression of induced pluripotent stem cell generation by the p53–p21 pathway

(2009) Hyenjong Hong et al.   NATURE

Mutant p53 Gain-of-Function in Cancer

(2009) M. Oren et al.   Cold Spring Harbor Perspectives in Biology

Clinical Outcomes and Correlates of TP53 Mutations and Cancer

(2009) A. I. Robles et al.   Cold Spring Harbor Perspectives in Biology

Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation

(2008) J. Zhang et al.   BLOOD

Hematopoiesis: An Evolving Paradigm for Stem Cell Biology

(2008) Stuart H. Orkin et al.   CELL

Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells

(2008) Pascale Flandrin et al.   CELL STRESS & CHAPERONES

Enrichment of hematopoietic stem cells with SLAM and LSK markers for the detection of hematopoietic stem cell function in normal and Trp53 null mice

(2008) Jichun Chen et al.   EXPERIMENTAL HEMATOLOGY

Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype

(2008) C Haferlach et al.   LEUKEMIA

Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors

(2008) Omobolaji O. Akala et al.   NATURE

Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways

(2008) Anwesha Dey et al.   NATURE REVIEWS DRUG DISCOVERY